Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Neovascular Age-Related Macular Degeneration Treatments
| NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENTS | ||||
|---|---|---|---|---|
| Generic | Brand | Strength | Form | Adult Dose |
| VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS | ||||
| brolucizumab-dbll | Beovu | 6mg/0.05mL | soln for intravitreal inj | 6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12wks |
| ranibizumab | Lucentis | 6mg/mL (0.3mg), 10mg/mL (0.5mg) | soln for intravitreal inj | 0.5mg (0.05mL of 10mg/mL) once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3mos after 4 monthly doses (less effective). Monitor regularly. |
| Byooviz1 | 10mg/mL (0.5mg) | soln for intravitreal inj | ||
| Cimerli1 | 6mg/mL (0.3mg), 10mg/mL (0.5mg) | soln for intravitreal inj | ||
| Susvimo1,2 | 100mg/mL | soln for intravitreal implant or intravitreal inj | 2mg (0.02mL of 100mg/mL) continuously delivered via implant. Refill every 24wks (approx. 6mos). Supplemental treatment: 0.5mg (0.05mL of 10mg/mL) intravitreal inj into the affected eye while implant is in place, as clinically needed. | |
| VEGF INHIBITOR + ANGIOPOIETIN-2 (ANG-2) INHIBITOR | ||||
| faricimab-svoa | Vabysmo | 120mg/mL | soln for intravitreal inj | 6mg (0.05mL) once every 4wks (approx. every 28 ± 7 days, monthly) for the 1st 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12wks later to determine whether to give a 6mg (0.05mL) dose on one of the following 3 regimens: (1) Weeks 28 and 44; (2) Weeks 24, 36 and 48; or (3) Weeks 20, 28, 36 and 44. |
| VEGF INHIBITOR + HUMAN IgG1 | ||||
| aflibercept | Eylea | 2mg/0.05mL | soln for intravitreal inj | 2mg (0.05mL) once every 4wks (approx. 28 days, monthly) for the 1st 12wks (3mos), followed by 2mg (0.05mL) once every 8wks (2mos); some may need the monthly dosing after the 1st 3mos. May also treat with 1 dose every 12wks after one year of successful therapy (not as effective); assess regularly. |
| Eylea HD | 8mg/0.07mL | soln for intravitreal inj | 8mg (0.07mL) once every 4wks (approx. every 28 days ± 7 days) for the 1st 3 doses, followed by 8mg (0.07mL) once every 8–16wks (± 1wk) | |
| PHOTOSENSITIZER | ||||
| verteporfin | Visudyne3 | 15mg per vial | pwd for IV infusion after reconstitution and dilution | Infuse over 10mins at a rate of 3mL/min. Usual dose: 6mg/m2. After infusion, the second step is activation of verteporfin with light from a nonthermal diode laser. Reevaluate every 3mos and if choroidal neovascular leakage is detected on fluorescein angiography, therapy should be repeated. |
| NOTES | ||||
|
1 Biosimilar to Lucentis. 2 In patients who have previously responded to at least 2 intravitreal injections of a VEGF inhibitor. 3 Consider for wet AMD patients with persistent intraocular fluid leakage, including anti-VEGF nonresponders. Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 9/2023) |
||||
